Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retinal diseases. The product is authorized in the European Union and United Kingdom for wet age-related macular degeneration (wet AMD), and… From the company’s description.
In fiscal 2025, Outlook Therapeutics, Inc. reported revenue of $1.41M and a net loss of $62.42M. Operations used $51.83M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Outlook Therapeutics, Inc. does
In the company’s own words
Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retinal diseases. The product is authorized in the European Union and United Kingdom for wet age-related macular degeneration (wet AMD), and the company launched it in Germany and the UK in June 2025. Its U.S. application for wet AMD was under FDA review following resubmission, while development plans also include diabetic macular edema and branch retinal vein occlusion. Bevacizumab inhibits vascular endothelial growth factor and is administered by intravitreal injection; the company’s product is intended for use by retina specialists as an approved ophthalmic alternative to repackaged bevacizumab. Outlook Therapeutics retains development and commercialization rights to LYTENAVA, except for licensed rights in the greater China market, and works with Cencora to support commercialization in Europe and the UK. The company has no reportable business segments described here, and its principal focus is LYTENAVA; it also retains rights to two legacy biosimilar candidates that are not in active development.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- ISELIN, NJ
- Fiscal year end
- September
- CIK
- 1649989
- SIC
- 2836
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Outlook Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Outlook Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Outlook Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Outlook Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Outlook Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”